Ads
related to: sox11 mantle cell lymphoma prognosis- FDA-Approved Use
Learn More About A Treatment
For You Or A Loved One With MCL.
- Patient Side Effects
Find Treatment Side Effect Info &
Other Resources On The Site.
- Study Data Available
View Study Data For A
Treatment For MCL Patients.
- Saving & Support Programs
Discover Savings & Support Programs
For A Treatment Option.
- Register For Updates
Register For Personalized Support &
Receive Updates About Your Disease.
- Caregiver Support Program
Access More Information About How
To Support A Loved One With MCL .
- FDA-Approved Use
Search results
Results From The WOW.Com Content Network
Mantle cell lymphoma (MCL) is a type of non-Hodgkin's lymphoma, comprising about 6% of cases. [ 1 ] [ 2 ] It is named for the mantle zone of the lymph nodes where it develops. [ 3 ] [ 4 ] The term 'mantle cell lymphoma' was first adopted by Raffeld and Jaffe in 1991.
Lymphocyte staining for SOX11 immunohistochemistry indicates mantle cell lymphoma (cyclin D1 positive and negative) rather than other mature lymphoid neoplasms or normal lymphocytes. [12] Mutations in SOX11 are associated with Coffin–Siris syndrome [13] and mantle cell lymphoma. [14]
In situ lymphoid neoplasia (ISLN, also termed in situ lymphoma) is a precancerous condition newly classified by the World Health Organization in 2016. The Organization recognized two subtypes of ISLN: in situ follicular neoplasia (ISFN) and in situ mantle cell neoplasia (ISMCL). [1]
Mantle cell lymphoma: The monoclonal B-cells in this aggressive lymphoma are CD5+ in most cases, CD10−, CD23−, CD43+, CD103−, complete Ig+, and express cyclin D1; these cells have translocations between chromosomes 11 and 14 in >95% of cases and in many cases overexpress the SOX11 transcription factor gene. [2]
What is non-Hodgkin lymphoma? Non-Hodgkin lymphoma (sometimes simply called NHL) is a form of blood cancer that strikes the white blood cells of the infection-fighting lymphatic system.
The International Prognostic Index (IPI) is a clinical tool developed by oncologists to aid in predicting the prognosis of patients with aggressive non-Hodgkin's lymphoma. Previous to IPI's development, the primary consideration in assessing prognosis was the Ann Arbor stage alone, but this was increasingly found to be an inadequate means of ...
Ads
related to: sox11 mantle cell lymphoma prognosis